Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

Schrödinger announced the formation of Tectora, a biotechnology company co-founded with NEA and RA Capital to develop therapies for immunology and inflammation. The new venture expands Schrödinger's biotech ecosystem and provides a vehicle for advancing potential AI-enabled drug-discovery programs, though no funding amount, pipeline assets, or financial terms were disclosed.